[Blinatumomab (acute lymphoblastic leukaemia, Ph-, CD19+, children aged 1 to 18 years) - Assessment according to §35a (para. 1., sentence 11) Social Code Book V]

Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen
Record ID 32018003989
Original Title: Blinatumomab (ALL mit Hochrisiko-Erstrezidiv: Kinder ≥ 1 bis < 18 Jahren))
Project Status: Completed
Year Published: 2021
English language abstract: There is no English language summary available
Publication Type: Full HTA
Country: Germany
MeSH Terms
  • Precursor B-Cell Lymphoblastic Leukemia-Lymphoma
  • Child
  • Antineoplastic Agents
  • Antibodies, Bispecific
  • Blinatumomab
  • Precursor Cell Lymphoblastic Leukemia-Lymphoma
  • Child
  • Adolescent
  • Health Care Costs
  • Epidemiology
Organisation Name: Institute for Quality and Efficiency in Health Care (IQWiG)
Contact Address: IQWiG, Im Mediapark, 8, DE-50670 Cologne, GERMANY, Tel: +49(0)221-35685, Fax: +49(0)221-356851
Contact Email: berichte@iqwig.de
Copyright: Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.